LNTH vs MYGN
Lantheus Holdings, Inc. and Myriad Genetics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | LNTH | MYGN |
|---|---|---|
| Revenue | $1.5B | $824.5M |
| Net income | $233.6M | $-365.9M |
| Gross margin | 61.1% | 69.9% |
| Net margin | 15.2% | −44.4% |
| Return on equity | 21.4% | −68.5% |
| Diluted EPS | $3.41 | −$3.95 |
| Dividend / share | — | — |
| Payout ratio | −0.2% | — |
| Free cash flow | $259.9M | $-151.6M |
| Equity | $1.1B | $368.0M |
| Net debt / equity | 0.19× | −0.08× |
| Current ratio | 2.70× | 2.49× |
| Revenue CAGR 5y | 35.3% | 8.2% |
| Profit CAGR 5y | — | — |
LNTH bills 1.9× the revenue of MYGN, and MYGN closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | LNTH | MYGN |
|---|---|---|
| FY2025 | $1.5B | $824.5M |
| FY2024 | $1.5B | $837.6M |
| FY2023 | $1.3B | $753.2M |
| FY2022 | $935.1M | $678.4M |
| FY2021 | $425.2M | $690.6M |
| FY2020 | $339.4M | $557.1M |
| FY2019 | $347.3M | $638.6M |
| FY2018 | $343.4M | $851.1M |
| FY2017 | $331.4M | $743.7M |
| FY2016 | $301.9M | $728.7M |
Net income by year
Bottom line
| Fiscal year | LNTH | MYGN |
|---|---|---|
| FY2025 | $233.6M | $-365.9M |
| FY2024 | $312.4M | $-127.3M |
| FY2023 | $326.7M | $-263.3M |
| FY2022 | $28.1M | $-112.0M |
| FY2021 | $-71.3M | $-27.2M |
| FY2020 | $-13.5M | $-223.6M |
| FY2019 | $31.7M | $-199.5M |
| FY2018 | $40.5M | $4.6M |
| FY2017 | $123.4M | $133.3M |
| FY2016 | $26.8M | $17.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry